Clinical Trials Logo

Filter by:
NCT ID: NCT01052337 Recruiting - Clinical trials for Spinal Cord Diseases

Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy

Blade runner
Start date: April 2009
Phase: Phase 4
Study type: Interventional

Aim of this trial is to compare propofol-based anaesthesia vs. sevoflurane-based anaesthesia induction in patients with cervical myelopathy receiving oral or nasal fiberoptic intubation.

NCT ID: NCT01093235 Recruiting - Breast Cancer Clinical Trials

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

Start date: April 2009
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving combination chemotherapy together with or without bevacizumab is more effective in treating patients with nonmetastatic breast cancer. PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy works compared with giving combination chemotherapy together with bevacizumab in treating patients with nonmetastatic breast cancer.

NCT ID: NCT01100840 Recruiting - Clinical trials for Non Small Cell Lung Cancer

A Retrospective Study of Biomarkers in Non-Small Cell Lung Cancer

Start date: April 2009
Phase: N/A
Study type: Observational

The purpose of this study is: 1. To characterize the types and frequency of molecular alterations to the epidermal growth factor receptor (EGFR) pathway, FGFR4 and EML-ALK in Asian patients with non-small cell lung cancer 2. To identify candidate biomarkers of importance in the EGFR and estrogen pathways Most, if not all, human malignancies including lung cancer are caused by somatic alterations of the genome, leading to activation of oncogenes or inactivation of tumor suppressor genes and their resultant oncogenic effects. In addition to mutations, increased chromosomal copy number (by amplification or polysomy) and DNA methylation are other mechanisms of oncogene activation and tumour suppressor gene inactivation respectively. Little is known about the relationship between these oncogenes of the EGFR family and the recently described oncogenes FGFR4 and fusion gene EML4-ALK. Recent data suggests molecularly defined subgroups of non-small cell lung cancer (NSCLC) exist and can be used to predict for sensitivity to targeted agents (erlotinib or gefitinib) or cytotoxic chemotherapy (pemetrexate, gemcitabine, platinum agents). The findings that estrogen receptors are present in lung tumours and that estrogen can stimulate growth and proliferation of lung cancers in vitro and in vivo are provocative. Further studies to evaluate the role of estrogens and other sex hormones in lung cancer are warranted. A further understanding of the molecular indicators of lung cancer prognosis and treatment prediction would improve drug development and patient treatment selection. Archived paraffin-embedded and fresh frozen NSCLC tumor tissue will be obtained via the Department of Pathology and the National University Tissue Repository respectively. Clinico-pathological characteristics will be obtained from the case records, Pathology and Tissue Repository. DNA will be isolated using standard techniques. Sequencing of genes in the EGFR signaling pathway: EGFR, KRAS, ErbB2, ErbB3, MET, PI3K, and BRAF as well as FGFR4. Unstained slides from the paraffin-embedded tissue will be obtained and subjected to fluoresce in vitro hybridization (FISH) for breakpoints in the EML4 and ALK genes as previously described. For cases that have been snap-frozen, RNA will be extracted and EML4-ALK fusions will be confirmed using RT-PCR and pre-specified primers. To analyse the expression of proteins of putative relevance to EGFR function (such as EGFR, ErbB2, ErbB3, AKT, MET, STAT, ERK, MAPK, cyclin D1, C/EBPa), downstream effects of EGFR: cell proliferation (Ki-67), angiogenesis (CD34, VEGF-A), apoptosis (bcl-2), metastasis, and hormonal influence (oestrogen and progesterone receptors, aromatase), TMA technology will be utilised. The status of the tumor suppressor genes PTEN and C/EBPa will be analysed.

NCT ID: NCT01125826 Recruiting - Brain Tumor Clinical Trials

Cell Culture of Glioma Specimens for in Vitro Preclinical Studies

Start date: April 2009
Phase: N/A
Study type: Observational

The purpose of this study is to culture primary human brain tumor cells with the specific aims of: 1. Develop primary cultures from human brain tumor surgical specimens 2. Determine the genetic and molecular fingerprints of brain tumors that may have prognostic significance 3. Delineate the mechanisms underlying oncogenesis of brain tumors. 4. Perform in vitro assays with brain tumor derived primary cultures to assess the efficacy of novel therapeutic agents.

NCT ID: NCT01198730 Recruiting - Clinical trials for Coronary Artery Disease

Screen of DM by OGTT in Subjects Receiving CAG or MDCT for CAD

Start date: April 2009
Phase:
Study type: Observational

To determine the glucose regulation status of patients who were suspected to have CAD in central Taiwan.

NCT ID: NCT01253746 Recruiting - Neural Tube Defects Clinical Trials

Genetics of Neural Tube Defects

NTD
Start date: April 2009
Phase: N/A
Study type: Observational

The Genetics of Neural Tube Defects Study at the University of Miami: The University of Miami John P. Hussman Institute for Human Genomics is looking for families to participate in research to identify the genetic and environmental factors that contribute to Neural Tube Defects (NTD). Our research goal is to better understand the genetic and environmental causes of both open NTD, like spina bifida and anencephaly, and closed NTD, like lipomeningocele and tethered cord. This will eventually lead to more accurate genetic counseling and risk assessment, improved treatments, and better prevention methods. Any individual with a diagnosis of NTD and his/her selected family members can participate, if willing. Participation is free. Travel is not required. Participation involves reading and signing a consent form, providing a blood sample, a family and medical history interview, and granting the research staff permission to review the medical records of the individual(s) with NTD. We maintain the highest standards of confidentiality for all families. If interested, please contact Maria Ciliberti, the study coordinator, at 1-877-686-6444 (toll free) or directly at 305-243-4360, or by email Mciliberti@med.miami.edu . Please visit our web site at www.hihg.org for more information.

NCT ID: NCT01306396 Recruiting - Clinical trials for Non-alcoholic Fatty Liver Disease

Effect of Fructose Reduction on Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome in Overweight Children

Start date: April 2009
Phase: N/A
Study type: Interventional

The aim of the present study is to find out if a dietary intervention mainly focusing on fructose reduction has a preventive effect on the development and progression of NAFLD and the metabolic syndrome in overweight children.

NCT ID: NCT01316744 Recruiting - Cancer Clinical Trials

Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain

Start date: April 2009
Phase: Phase 3
Study type: Interventional

RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given together with the best pain management in treating neuropathic pain in patients with cancer. PURPOSE: This randomized phase III trial is studying ketamine hydrochloride given together with the best pain management to see how well it works compared with giving a placebo together with the best pain management in treating cancer patients with neuropathic pain.

NCT ID: NCT01363739 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab

PROVETTA
Start date: April 2009
Phase: N/A
Study type: Observational

-1498C/T VEGF polymorphism, as suggested by a recent retrospective analysis, seems to have a role in predicting the efficacy of Bevacizumab plus FOLFIRI in first-line treatment of metastatic colorectal cancer patients. The present study aims to prospectively evaluate the predictive role of this polymorphism in metastatic colorectal patients receiving the same treatment.

NCT ID: NCT01386788 Recruiting - Clinical trials for Smoke Inhalation Patients

European Survey: Risk of Cyanide Poisoning in Smoke Inhalation

RISK
Start date: April 2009
Phase: N/A
Study type: Observational

Cyanide poisoning is commonly viewed as a rare but dramatic event, occurring in industrial or laboratory settings as the result of accidental releases of hydrogen cyanide (HCN) gas (e.g. in the case of fire) or salts in the case of suicide attempts. In fact, cyanide poisoning is considerably more common than is generally appreciated. Multiple clinical and post-mortem studies have demonstrated that HCN contributes to the toxicity of fire smoke. Cyanide acts primarily through its strong affinity for the iron-containing heme moiety, binding to numerous critical enzyme systems in the body and rendering them inactive. Of late, increasing attention has been paid to the relationship of cyanide and nitric oxide. The interactions appear to be complex, with cyanide inducing nitric oxide production by binding to N-methyl-D-aspartate (NMDA) receptors, as well as binding to nitric oxide synthase. The latter may be overcome by the presence of nitric oxide synthase inhibitors. Probably, the majority of the cyanide poisoning cases are due to smoke inhalation in closed-space fires. So far, there are no clear data available on the prevalence of cyanide poisoning in smoke inhalation. This information would be of great interest for all emergency physicians since a proven or supposed cyanide poisoning does not only requires an intensive supportive care, including the administration of supplemental oxygen and artificial ventilation, blood pressure support, and anticonvulsants, but also a rapid administration of a cyanide antidote. Therefore, it is the goal of this survey to assess the prevalence of cyanide poisoning in smoke inhalation victims. Only the data of patients with a cyanide measurement before specific antidote treatment will be included